Cemiplimab plus chemotherapy versus chemotherapy in non-small-cell lung cancer with PD-L1 ≥1%: 5-year update of EMPOWER-Lung 3 Part 2 results.
Researchers
M Gogishvili, T Makharadze, T Melkadze, D Giorgadze, K Penkov, K Laktionov, E Kalinka, G Nemsadze, M Nechaeva, I Rozhkova, D A G McIntyre, X Jia, M Kaul, S Chua, K Gillis, F Seebach, H Magnan, E Kim, A Baramidze
Abstract
EMPOWER-Lung 3 Part 2, a phase 3, double-blind, placebo-controlled study, demonstrated substantial survival benefits with cemiplimab plus chemotherapy versus placebo plus chemotherapy in patients with previously untreated advanced non-small-cell lung cancer (NSCLC) without EGFR, ALK, or ROS1 alterations. Here, we report 5-year results from the subgroup analysis of patients with programmed death-ligand 1 (PD-L1) expression ≥1%. Eligible patients were randomized 2 : 1 to receive histology-specific platinum-doublet chemotherapy plus cemiplimab 350 mg or placebo every 3 weeks for up to 108 weeks. The primary endpoint was overall survival (OS); secondary endpoints included progression-free survival (PFS) and objective response rate (ORR). This analysis focuses on patients with PD-L1 ≥1% with 5-year follow-up (last patient last visit: 27 February 2025). Of 327 patients with PD-L1 ≥1% (out of 466 in the overall study), 217 received cemiplimab plus chemotherapy and 110 received placebo plus chemotherapy. After median follow-up of 60.5 months, median OS for cemiplimab plus chemotherapy was 24.0 months [95% confidence interval (CI) 20.9-28.4] versus 12.1 months (95% CI 10.1-15.7) for placebo plus chemotherapy [hazard ratio (HR) 0.54, 95% CI 0.41-0.70, P < 0.0001); median PFS was 8.3 months (95% CI 6.7-10.8) versus 5.5 months (95% CI 4.3-6.2, HR 0.50, 95% CI 0.39-0.65, P < 0.0001), and the ORR was 48.4% versus 22.7%, respectively. Improved efficacy over placebo plus chemotherapy was observed across squamous and nonsquamous histologies, in both locally advanced and metastatic disease, and in patients with PD-L1 1%-49% and ≥50%. Grade ≥3 treatment-emergent adverse events occurred in 48.8% of patients receiving cemiplimab plus chemotherapy versus 27.5% receiving placebo plus chemotherapy. No new toxicities were identified. First-line cemiplimab plus chemotherapy continued to show durable clinical benefit versus placebo plus chemotherapy after 5 years of follow-up in PD-L1-positive advanced NSCLC.Source: PubMed (PMID: 43035066)View Original on PubMed